1. Short title This Act may be cited as the Expanding Access to Low-Cost Generics Act of 2019 . 2. 180-day exclusivity period (a) In general Section 505(j)(5)(B)(iv) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(j)(5)(B)(iv) ) is amended— (1) in subclause (I), by striking effective on the date that is 180 days after and all that follows through the period at the end and inserting the following: “effective— (aa) except as provided in item (bb), on the date that is 180 days after the date of the first commercial marketing of the drug (including the commercial marketing of the listed drug) by any first applicant; or (bb) if, in an infringement action brought in a district court solely against the applicant for the application described in this subclause (or any affiliate of the applicant), or an action in a district court for a declaratory judgment brought by that applicant, with respect to each patent to which a first applicant had submitted and lawfully maintained a certification under paragraph (2)(A)(vii)(IV), the district court decides that each patent is invalid or not infringed (including any substantive determination that there is no cause of action for patent infringement or invalidity), and the applicant for the application described in this subclause meets the requirements under subclause (III), immediately upon the district court entering such decision for such applicant. ; and (2) by adding at the end the following: (III) Applicant requirements The requirements under this subclause are that the applicant for the application described in subclause (I)— (aa) does not stay the action described in item (bb) of such subclause; (bb) does not agree to be bound by a judgment as to another applicant